Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361480 | 0.93 | MEN1 (0.37) | MEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL6217706 | 0.89 | GNRHR (0.39) | TP53MAPTSMN1; SMN2CNR2 | |
| SCHEMBL6242827 | 0.88 | MEN1 (0.36) | MEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL6504017 | 0.87 | CYP3A4 (0.42) | MEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL6217704 | 0.87 | PTGER4 (0.34) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL6499432 | 0.83 | MEN1 (0.38) | MEN1KMT2AMAPT | |
| SCHEMBL6218691 | 0.82 | GNRHR (0.39) | TP53SMN1; SMN2CNR2 | |
| SCHEMBL6247921 | 0.81 | GNRHR (0.41) | TP53SMN1; SMN2CNR2 | |
| SCHEMBL6276414 | 0.80 | PTGER4 (0.34) | MEN1KMT2ATP53MAPTCNR2 | |
| SCHEMBL6247538 | 0.79 | GNRHR (0.41) | TP53SMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | MEN1 4565/4885KMT2A 249/4885TP53 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.